Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 4/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | PLAU | P00749 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7140320 | 0.86 | F2 (0.47) | MEN1KMT2APLAU | |
| SCHEMBL5847197 | 0.84 | CYP1A2 (0.48) | ALDH1A1RAB9ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3247707 | 0.84 | F2 (0.60) | — | |
| SCHEMBL3247710 | 0.81 | P2RX7 (0.43) | MEN1KMT2AALDH1A1RAB9ACYP1A2 | |
| SCHEMBL7139994 | 0.81 | HSD17B10 (0.48) | KMT2AALDH1A1CYP1A2CYP2C9CYP2C19 | |
| Tenamfetamine SCHEMBL7407959 | 0.81 | TAAR1 (0.46) | KMT2AALDH1A1RAB9ALMNANPC1 | |
| SCHEMBL5885589 | 0.80 | F2 (0.59) | ALDH1A1RAB9A | |
| SCHEMBL8205180 | 0.80 | TPSAB1 (0.52) | CYP2C9TSHRPLAU | |
| SCHEMBL7912621 | 0.80 | TPSAB1 (0.61) | KMT2AALDH1A1L3MBTL1HPGDKDM4E | |
| SCHEMBL7403728 | 0.80 | TPSAB1 (0.49) | PLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1589029-B1 | Pyrazinone protease inhibitors | ORTHO MCNEIL PHARM INC (US) | 2010-03-17 | — | — | EP | claimed |
| EP-1589029-A2 | Pyrazinone protease inhibitors | Johnson & Johnson Pharmaceutical Research & Development L.L.C. (US) | 2005-10-26 | — | — | EP | claimed |
| EP-1589029-B1 | Pyrazinone protease inhibitors | ORTHO MCNEIL PHARM INC (US) | 2010-03-17 | — | — | EP | disclosed |
| US-7030110-B2 | Cyclic oxyguanidine pyrazinones as protease inhibitors | ORTHO-MCNEIL PHARMACEUTICALS, INC. (US) | 2006-04-18 | — | — | US | disclosed |
| US-20060058291-A1 | Cyclic oxyguanidine pyrazinones as protease inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2006-03-16 | — | — | US | disclosed |
| EP-1589029-A2 | Pyrazinone protease inhibitors | Johnson & Johnson Pharmaceutical Research & Development L.L.C. (US) | 2005-10-26 | — | — | EP | disclosed |
| EP-1086122-B1 | PYRAZINONE PROTEASE INHIBITORS | JOHNSON & JOHNSON PHARM RES (US) | 2005-08-24 | — | — | EP | disclosed |
| EP-0997474-B1 | Antithrombotic agents | PFIZER (US) | 2003-10-29 | — | — | EP | disclosed |
| EP-1303510-A2 | CYCLIC OXYGUANIDINE PYRAZINONES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2003-04-23 | — | — | EP | disclosed |
| US-20030073702-A1 | Cyclic oxyguanidine pyrazinones as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-04-17 | — | — | US | disclosed |
| US-6514978-B2 | Compounds such as 1-(n-(2-(amidinoaminooxy)ethyl)amino) carbonylmethyl-6-methyl-3-(phenethylamino)-pyrazinone attached to a polymer coated onto a medical device for blood collection or storage; antiagglomerants | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-02-04 | — | — | US | disclosed |
| US-5981546-A | Integrin antagonists | MERCK & CO., INC. (US) | 1999-11-09 | — | — | US | disclosed |
| EP-0934305-A1 | INTEGRIN ANTAGONISTS | Merck & Co., Inc. (US) | 1999-08-11 | — | — | EP | disclosed |
| US-5932606-A | Pyrazinone, pyridinone, piperidine and pyrrolidine thrombin inhibitors | MERCK & CO., INC. (US) | 1999-08-03 | — | — | US | disclosed |
| WO-1999011267-A1 | PYRAZINONE THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 1999-03-11 | — | — | WO | disclosed |
| EP-0900207-A1 | PYRAZINONE THROMBIN INHIBITORS | Merck & Co., Inc. (US) | 1999-03-10 | — | — | EP | disclosed |
| US-5866573-A | Pyrazinone thrombin inhibitors | MERCK & CO., INC. (US) | 1999-02-02 | — | — | US | disclosed |
| WO-1998042342-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 1998-10-01 | — | — | WO | disclosed |
| WO-1998008840-A1 | INTEGRIN ANTAGONISTS | MERCK & CO., INC. (US) | 1998-03-05 | — | — | WO | disclosed |
| WO-1997040024-A1 | PYRAZINONE THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 1997-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073702-A1 | Cyclic oxyguanidine pyrazinones as protease inhibitors | PLG, SERPINE1, TFPI | MEN1 4642/4885KMT2A 3878/4885ALDH1A1 2762/4885 |
| US-20060058291-A1 | Cyclic oxyguanidine pyrazinones as protease inhibitors | PLG, TFPI, F12 | MEN1 4521/4885KMT2A 3535/4885ALDH1A1 3782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.